These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 37066788)

  • 1. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
    J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Madhani A; Sabogal N; Massillon D; Paul LD; Rodriguez C; Fine D; Helmke S; Winburn M; Kurian D; Raiszadeh F; Teruya S; Cohn E; Einstein AJ; Miller EJ; Connors LH; Maurer MS; Ruberg FL
    J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of Body Mass Index to Transthyretin Cardiac Amyloidosis Particularly in Black and Hispanic Patients (from the SCAN-MP Study).
    Poterucha TJ; Kurian D; Raiszadeh F; Teruya S; Elias P; Kogan R; Chiuzan C; Einstein AJ; Ruberg FL; Maurer MS
    Am J Cardiol; 2022 Aug; 177():116-120. PubMed ID: 35705430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
    Ruberg FL; Maurer MS
    JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
    Lau ATC; DiDomenico RJ; Kim K
    Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
    Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
    J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
    Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis.
    Barker N; Judge DP
    Am J Cardiol; 2022 Dec; 185 Suppl 1():S43-S50. PubMed ID: 36216601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.
    Damrauer SM; Chaudhary K; Cho JH; Liang LW; Argulian E; Chan L; Dobbyn A; Guerraty MA; Judy R; Kay J; Kember RL; Levin MG; Saha A; Van Vleck T; Verma SS; Weaver J; Abul-Husn NS; Baras A; Chirinos JA; Drachman B; Kenny EE; Loos RJF; Narula J; Overton J; Reid J; Ritchie M; Sirugo G; Nadkarni G; Rader DJ; Do R
    JAMA; 2019 Dec; 322(22):2191-2202. PubMed ID: 31821430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
    Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era.
    Martyn T; Saef J; Hussain M; Ives L; Kiang A; Estep JD; Collier P; Starling RC; Cremer PC; Tang WHW; Hanna M; Jaber WA
    J Card Fail; 2022 Oct; 28(10):1509-1518. PubMed ID: 35843490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATTR Epidemiology, Genetics, and Prognostic Factors.
    Obi CA; Mostertz WC; Griffin JM; Judge DP
    Methodist Debakey Cardiovasc J; 2022; 18(2):17-26. PubMed ID: 35414855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
    JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
    Razvi Y; Ioannou A; Patel RK; Chacko L; Karia N; Riefolo M; Porcari A; Rauf MU; Starr N; Ganesananthan S; Blakeney I; Kaza N; Filisetti S; Bolhuis RE; Rowczenio D; Gilbertson J; Hutt D; Mahmood S; Lachmann HJ; Wechalekar AD; Kotecha T; Knight DS; Coghlan JG; Petrie A; Whelan CJ; Venneri L; Martinez-Naharro A; Hawkins P; Fontana M; Gillmore JD
    Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Pitfall and Clinical Characteristics of Variant Versus Wild-Type Transthyretin Amyloid Cardiomyopathy in Asian Population: The Korean Nationwide Cohort Study.
    Kim D; Youn JC; Lee HW; Oh J; Son JW; Cho HJ; Lee S; Shah NR; Kittleson MM; Jeon ES
    J Korean Med Sci; 2024 May; 39(19):e163. PubMed ID: 38769922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis.
    Batra J; Rosenblum H; Cappelli F; Zampieri M; Olivotto I; Griffin JM; Saith SE; Teruya S; De Los Santos J; Argiro A; Burkhoff D; Perfetto F; Maurer MS
    J Card Fail; 2022 Jun; 28(6):950-959. PubMed ID: 34974181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.